Loomis, Sayles & Company
ISEE

Loomis, Sayles & Company’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Loomis, Sayles & Company’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-290,108
Closed -$14.8M – 1085
2016
Q2 		$14.8M Buy
290,108
+52,540
+22% +$2.61M 0.04% 354
2016
Q1 		$10M Buy
+237,568
New +$12.1M 0.03% 414

Other funds holding ISEE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Loomis, Sayles & Company's ISEE Position: Q3 2016 in Review

Loomis, Sayles & Company sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2016, closing a stake of 290,108 shares — an estimated $14.8M sold.

Loomis, Sayles & Company first reported a position in ISEE in Q1 2016 and held it in 2 quarters. The position peaked at $14.8M in Q2 2016. 191 funds tracked by Wall St. Rank hold ISEE as of Q3 2016.

  • Loomis, Sayles & Company reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 290,108 IVERIC bio, Inc. Common Stock shares in Q3 2016, an estimated $14.8M.
  • Loomis, Sayles & Company first reported a position in IVERIC bio, Inc. Common Stock in Q1 2016 and held it in 2 quarters.
  • Loomis, Sayles & Company's IVERIC bio, Inc. Common Stock position peaked at $14.8M in Q2 2016.
  • 191 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2016.

Based on Loomis, Sayles & Company's 13F filing for Q3 2016, filed 14 Nov 2016.